Last Updated:
Searching
Create account to add to watchlist!
Create account to add to watchlist!

Integrated Wellness Acquisition Corp - WEL

  • Commons

    $9.97

    +0.00%

    WEL Vol: 0.0

  • Warrants

    $0.17

    +0.00%

    WEL+ Vol: 0.0

  • Units

    $10.03

    +0.00%

    WEL= Vol: 0.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 114.9M
Average Volume: 15.2K
52W Range: $9.80 - $10.06
Weekly %: +0.00%
Monthly %: +0.40%
Inst Owners: 0

Info

Target: Searching
Days Since IPO: 206
Unit composition:
Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant
Trust Size: 10000000.0M

🕵Stocktwit Mentions

Last10K posted at 2022-05-16T12:38:53Z

$WEL just filed a 10-Q Quarterly Report with 42 sections and 4 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/wel/0001193125-22-150930.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=wel

Quantisnow posted at 2022-05-16T12:07:24Z

$WEL 📜 SEC Form 10-Q filed by Integrated Wellness Acquisition Corp https://quantisnow.com/i/2890555?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-05-16T12:06:34Z

$WEL Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/aeea49113a46111dbef316ce21a267d2

shortablestocks posted at 2022-05-02T19:46:28Z

Zero shares available to short currently in $WEL. https://www.shortablestocks.com/?WEL

macroaxis posted at 2022-04-29T12:27:03Z

$WEL - Latest headline from www.fiercehealthcare.com:… https://www.macroaxis.com/stock-analysis/WEL/Integrated-Wellness-Acquisition #insidertrading #stocks #fintechnews

EarningsInsider posted at 2022-04-27T11:09:30Z

Echelon Wealth Partners Sets WELL Health Technologies Q1 2022 Earnings Estimates at ($0.02) EPS. https://www.marketbeat.com/x/1225191 $WEL.

Last10K posted at 2022-04-01T10:57:08Z

$WEL just filed a 10-K Annual Report with 47 sections and 5 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/wel/0001193125-22-092380.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=wel

Newsfilter posted at 2022-04-01T10:26:28Z

$WEL Form NT 10-K (notification of inability to timely file form 10-k 405, 10-k, 10-ksb 405, 10-ksb, 10-kt, or 10-kt405) filed with the SEC https://newsfilter.io/a/0cfec0e1ba33648daeb80d24660b8ffc

Quantisnow posted at 2022-04-01T10:25:18Z

$WEL 📜 SEC Form NT 10-K filed by Integrated Wellness Acquisition Corp https://quantisnow.com/i/2662119?utm_source=stocktwits 45 seconds delayed.

Quantisnow posted at 2022-04-01T10:15:15Z

$WEL 📜 SEC Form 10-K filed by Integrated Wellness Acquisition Corp https://quantisnow.com/i/2661940?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-04-01T10:14:26Z

$WEL Form 10-K (annual report [section 13 and 15(d), not s-k item 405]) filed with the SEC https://newsfilter.io/a/dbb8ad78329e8340c5649a90f78f2c14

Quantisnow posted at 2022-02-09T21:33:47Z

$WEL 📜 SEC Form SC 13G filed by Integrated Wellness Acquisition Corp https://quantisnow.com/insight/2383053?s=s 45 seconds delayed.

Newsfilter posted at 2022-02-09T21:33:01Z

$WEL Form SC 13G (statement of acquisition of beneficial ownership by individuals) filed with the SEC https://newsfilter.io/a/e982b9e486c26db6718fe46b7e1a0935

macroaxis posted at 2022-01-30T06:13:03Z

$WEL - Exchange listing can cause some chaos for Integrated Wellness #stocks #earnings

dividendinvestorbyeagle posted at 2022-01-21T13:56:59Z

$WEL hit 52 week high (Integrated Wellness Acquisition Corp) https://www.dividendinvestor.com/dividend-news/?symbol=wel

tradethehalt posted at 2022-01-18T21:01:04Z

Today's Top 5 Gainers Report: $WEL (228%) $BBI (60%) $DATS (39%) $INDO (31%) $NURO (29%) Alerts & Technical Analysis via tradethehalt.com

603COIN posted at 2022-01-18T17:03:44Z

$WEL

tradethehalt posted at 2022-01-18T17:01:04Z

Mid-Day Top 5 Gainers Report: $WEL (228%) $BBI (87%) $MYNZ (39%) $NURO (37%) $NEPT (30%) If we missed a split/reverse split, let us know!

Last10K posted at 2022-01-13T11:06:12Z

$WEL just filed with the SEC a Financial Exhibit https://last10k.com/sec-filings/WEL/0001193125-22-007890.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=WEL

Newsfilter posted at 2022-01-13T11:03:32Z

$WEL Form 8-K: Separate Trading of Class A Ordinary Shares and Warrants On January 12, 2022, Integrated Wellness Acquisition Corp announced that, commencing on January 18, 2022, the holders of units i.. https://newsfilter.io/a/563d4cad225cf05eb0637725886bf1e8

Stonkmoon posted at 2022-01-12T22:57:40Z

$WEL 2022-01-12 17:54 ET Integrated Wellness Acquisition Corp Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing January 18, 2022 INTEGRATED WELLNESS ACQUISITION CORP https://stonkmoon.com/news/WEL/8fe5fedc4e49443605fda3a1b76db71b

Newsfilter posted at 2022-01-12T22:55:02Z

$WEL Integrated Wellness Acquisition Corp Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing January 18, 2022 https://newsfilter.io/a/92f075456d1432ec4a0231360df0d247

Stock_Titan posted at 2022-01-12T22:54:56Z

$WEL Integrated Wellness Acquisition Corp Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing January 18, 2022 https://www.stocktitan.net/news/WEL-UN/integrated-wellness-acquisition-corp-announces-the-separate-trading-n1wqsfuer6zv.html

Last10K posted at 2021-12-17T21:44:23Z

$WEL just filed with the SEC a Financial Exhibit https://last10k.com/sec-filings/WEL/0001193125-21-361117.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=WEL

Newsfilter posted at 2021-12-17T21:17:01Z

$WEL Form 8-K: On December 13, 2021, Integrated Wellness Acquisition Corp consummated its initial public offering of 11,500,000 units, including 1,500,000 Units issued pursuant to the full exercise of.. https://newsfilter.io/a/f5847630cb9415323cd2a26e42b7bf93

Newsfilter posted at 2021-12-17T16:59:18Z

$WEL Form SC 13G (statement of acquisition of beneficial ownership by individuals) filed with the SEC https://newsfilter.io/a/7bb12895fbe0bf7ad9a0a0284d6fe488

Last10K posted at 2021-12-13T21:21:49Z

$WEL just filed with the SEC a New Agreement, a Unregistered Sales, a Bylaw Change and a Financial Exhibit https://last10k.com/sec-filings/WEL/0001193125-21-355407.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=WEL

Newsfilter posted at 2021-12-13T21:17:50Z

$WEL Form 8-K: Entry into a Material Definitive Agreement. On December 13, 2021, Integrated Wellness Acquisition Corp consummated its initial public offering of 11,500,000 units, including 1,500,000 U.. https://newsfilter.io/a/8514fc4e44deb7086dbeceada77d6e6b

Stock_Titan posted at 2021-12-13T18:58:43Z

$WEL Integrated Wellness Acquisition Corp Announces Closing of $115 Million Initial Public Offering, Including the Full Exercise of the Over-Allotment Option https://www.stocktitan.net/news/WEL/integrated-wellness-acquisition-corp-announces-closing-of-115-46w47o596hwr.html #offering #IPO

Newsfilter posted at 2021-12-09T22:31:13Z

$WEL Form 424B4 (prospectus [rule 424(b)(4)]) filed with the SEC https://newsfilter.io/a/56cd79f45db7bbadb8a10eb1854fc201

Management

Our officers, directors and director nominees are as follows: Name Age Title Steven Schapera 61 Chief Executive Officer and Director Antonio Varano Della Vergiliana 64 Chairman of the Board James MacPherson 53 Chief Financial Officer and Director Nominee Robert Quandt 42 Chief Operating Officer and Director Nominee Gael Forterre 40 Director Nominee Scott Powell 48 Director Nominee Hadrien Forterre 32 Director Nominee Our directors, director nominees and executive officers are as follows: Antonio Varano Della Vergiliana, our director since inception and our Chairman since August 3, 2021, has more than thirty years of experience in the health and beauty industries, including working with companies focused on skin care, color cosmetics, and supplements. Since July 2018, Mr. Varano has served as the Chairman of the board of directors of Wellfully Ltd. (ASX:WFL), a fully-integrated science based wellness company. Mr. Varano is the founder and member of the board of directors of Artedomus, a leading Australian supplier of goods for commercial and residential architectural projects, since October 1985. Mr. Varano has served on the board of directors of New Hampton Technologies, LLC, a motorcycle security device manufacturer, since April 2006. Mr. Varano has also served on the board of directors of Path Group Inc., a software-as-a-service company, since October 2017. Mr. Varano was previously the Chairman of the BECCA Cosmetics group from 2001 to 2012 until its sale to Luxury Brand Partners and subsequent sale to Estée Lauder in 2016. Mr. Varano received his M.B.A from the University of Western Australia. We believe he is well qualified to serve on our board of directors due to his extensive experience in strategy, entrepreneurship, business development and management. Steven Schapera, our director since inception and our Chief Executive Officer since August 3, 2021, has more than 25 years of international experience in finding, scaling, operating and exiting successful businesses in the health, beauty and wellness industries. Mr. Schapera has been an operating partner with Capital D, Management LLP, a private equity firm, focused on investing in disruptive mid-market businesses, since January 2018. Mr. Schapera served on the board of directors of Invincible Brands GmbH, a consumer branding company focusing on health, beauty and fitness products, since January 2018. Since September 2019, Mr. Schapera has served as Chairman of Crowd Media Holdings Ltd. (ASX:CM8), and since May 2021 he also has served as Chairman of SIMRIS Inc. (SIMRIS-B.ST), a biotech company devoted to sustainable development and production of products and ingredients from farmed microalgae. Mr. Schapera has also served on the board of directors of Wild Nutrition Limited since May 2017 and Wellfully Ltd since August 2017. Mr. Schapera was the co-founder of the BECCA Cosmetics group in 2001, and initiated and managed the partial sale of BECCA to Luxury Brand Partners in 2012, which in turn led to the subsequent sale of BECCA to Estée Lauder in 2016. We believe he is well qualified to serve on our board of directors due to his extensive experience in founding, scaling, operating and exiting successful brand-oriented businesses in the health, beauty and wellness space. James MacPherson, our Chief Financial Officer since August 3, 2021 and one of our director nominees, is experienced in developing financial and supply chain capabilities for hyper-growth organizations. Mr. MacPherson has served as a member of the board of directors for the International Beauty Association since July 2021. Mr. MacPherson initiated and managed the public company readiness program for Olaplex, Inc., resulting in the company filing a registration statement for its initial public offering in August 2021. Mr. MacPherson served as the Chief Financial Officer of Olaplex, Inc., where he was responsible for all finance, supply chain and IT functions from May 2020 to June 2021 and as Senior Advisor from June 2021 to August 128 Table of Contents 2021. Mr. MacPherson has also served as the Chief Financial Officer and Chief Operating Officer of the BECCA Cosmetics group from August 2011 through November 2016 when the company was acquired by the Estee Lauder Companies Inc. Mr. MacPherson was also the Chief Financial Officer of Carol’s Daughter from August 2008 to July 2011 and the Chief Financial Officer of GoSmile, Inc. from March 2006 to July 2008. Mr. MacPherson worked for The Estee Lauder Companies Inc. (Clinique) in a succession of finance and sales leadership roles from August 1997 to July 2003. Mr. MacPherson earned a B.S. (Honors) in Accounting and an M.B.A. in both Finance and Information Systems from the Stern School of Business at New York University. We believe he is well qualified to serve on our board of directors due to his extensive experience in scaling business and driving financial performance in consumer goods companies in the beauty sector. Robert Quandt, our Chief Operating Officer since August 3, 2021 and one of our director nominees, has significant experience in business operations, finance and strategy. Mr. Quant has served as a Managing Director of JCL Investments, a Berlin-based private investment firm focusing on start-up companies, since August 2019. Mr. Quant has served on the board of directors of listed company SIMRIS Inc. since May 2021. Mr. Quant served as Chief Financial Officer and Chief Operating Officer for Invincible Brand from March 2017 to July 2019. From September 2019 to June 2021, Mr. Quant served as consultant and director of listed company Crowd Media Holdings Ltd. From January 2005 to August 2014, Mr. Quant served as a strategy consultant and Principal at Booz & Company. From August 2015 to February 2017, Mr. Quant served as the strategy lead at Linde AG for their North America and South America businesses. Mr. Quant earned a Master degree in Industrial Management of Technical University from Berlin. We believe he is well qualified to serve on our board of directors due to his extensive experience in finance and operations. Scott Powell, one of our director nominees, has served as Head of Investor Relations for VolitionRx Limited (NYSE American: VNRX), a company focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases, since May 2014 and as Chief Financial Officer of Volition America, Inc. since February 2017. Since January 2019, he has served as the President and Chief Executive Officer of Skyline Corporate Communications Group, LLC, an investor relations and corporate communications agency. From December 2009 to February 2013, he served as a Managing Director for MZ Group, an independent investor relations agency, and from July 2014 to May 2015, he served as the U.S. investor relations representative for Himax Technologies, Inc. (NASDAQ: HIMX), and Director of Investor Relations for China Hydroelectric Corporation (formerly NYSE: CHC) from March 2013 to July 2014. From August 2009 and December 2009, he was an investment banker with Brean Capital, LLC, and from October 2006 to August 2008, he was an investment banker with Westminster Securities in New York City. Mr. Powell was formerly an Adjunct Assistant Professor at Fordham University’s Gabelli Graduate School of Business from September 2013 to December 2017. Mr. Powell earned a Certificate in General Business from Columbia University, a Ph.D. and a Master of Arts from Brown University and a Bachelor of Science in Business Administration from Bryant University. We believe he is well qualified to serve on our board of directors due to his extensive experience in capital markets, finance, corporate communications, and investor relations. Gael Forterre, one of our director nominees, has served as the Chief Commercial Officer of VolitionRx Limited since January 2021 and he has been a managing partner of Armori Capital Management LLC since October 2013. Mr. Forterre served as a director of Path Education Inc., an education technology company which consummated a business combination with Path Group Inc., an Australian blank-check company in May 2021. Mr. Forterre also served as Path’s Chief Financial Officer from January 2018 to December 2018, and as Path’s Chief Executive Officer from January 2019 to December 2020. Mr. Forterre is the co-founder of Article22, a design-focused social enterprise, and also served on its board of directors from July 2013 to June 2021. Mr. Forterre started his career in February 2004 as a hedge fund analyst for an event-driven fund managed by Systeia Capital Management and then joined Alteram Asset Management in March 2005. In September 2005, Mr. Forterre joined the commodity derivative team at BNP Paribas in their New York office. Mr. Forterre earned a Master’s Degree in finance from Sorbonne Paris I and a double M.B.A from Columbia Business School and the London Business School. Mr. Forterre is the brother of Hadrien Forterre, one of our director nominees. We believe he is well qualified to serve on our board of directors due to his extensive experience in investing in and supporting fast growing companies. 129 Table of Contents Hadrien Forterre, one of our director nominees, has served as the General Counsel and Vice President of Strategic Projects at Path Group Inc. since September 2020. Mr. Forterre was formerly an associate at Arendt & Medernach SA in Luxembourg from August 2012 and August 2014 and at Herbert Smith Freehills LLP in London from August 2014 and January 2018, where he advised clients on a range of transactions, including fund formation, initial public offerings, mergers and acquisitions and related financings. Mr. Forterre served as legal and business advisor to Wellfully Ltd from September 2018 to December 2019. Mr. Forterre earned Master of Laws from University Paris Nanterre, an L.L.M. from Duke University and an M.B.A from Columbia University. Mr. Forterre is the brother of Gael Forterre, one of our director nominees. We believe he is well qualified to serve on our board of directors due to his extensive experience in corporate transactions (including initial public offerings and mergers and acquisitions), and investor relations. Number and Terms of Office of Officers and Directors Our board of directors is divided into three classes, with only one class of directors being elected in each year, and with each class (except for those directors appointed prior to our first annual meeting of shareholders) serving a three-year term. In accordance with the NYSE corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following our listing on the NYSE. The term of office of the first class of directors, consisting of James MacPherson and Robert Quandt, will expire at our first annual meeting of shareholders. The term of office of the second class of directors, consisting of Gael Forterre and Hadrien Forterre, will expire at our second annual meeting of shareholders. The term of office of the third class of directors, consisting of Antonio Varano Della Vergiliana, Steven Schapera and Scott Powell, will expire at our third annual meeting of shareholders. Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our founder shares. In addition, prior to the completion of an initial business combination, holders of a majority of our founder shares may remove a member of the board of directors for any reason. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and restated memorandum and articles of association as it deems appropriate. Our amended and restated memorandum and articles of association provides that our officers may consist of one or more chairman of the board, chief executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. Director Independence NYSE listing rules require that a majority of our board of directors be independent within one year of our initial public offering. An “independent director” is defined generally as a person that satisfies the applicable objective standards set forth in the listing rules and that, in the opinion of the company’s board of directors, has no material relationship with the listed company (either directly or as a partner, stockholder or officer of an organization that has a relationship with the company). Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect to have four “independent directors” as defined in the NYSE listing rules and applicable SEC rules. Our board has determined that each of Gael Forterre, Hadrien Forterre, Scott Powell and Antonio Varano Della Vergiliana is an independent director under applicable SEC and the NYSE listing rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive Officer and Director Compensation None of our executive officers or directors have received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on the NYSE through the earlier of consummation of 130 Table of Contents our initial business combination and our liquidation, we will reimburse our sponsor or an affiliate of our sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. In addition, our sponsor, executive officers and directors, or their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our sponsor, executive officers or directors, or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or their respective affiliates, prior to completion of our initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, our board of directors will have three standing committees: an audit committee, a nominating and corporate governance committee and a compensation committee. Subject to phase-in rules and a limited exception, the rules of the NYSE and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to phase-in rules and a limited exception, the rules of the NYSE require that the compensation committee and the nominating and corporate governance committee of a listed company be comprised solely of independent directors. Each committee will operate under a charter that will be approved by our board of directors and will have the composition and responsibilities described below. Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Gael Forterre, Scott Powell and Antonio Varano Della Vergiliana will serve on our audit committee. Our board of directors has determined that Gael Forterre, Scott Powell and 131 Table of Contents Antonio Varano Della Vergiliana are independent under the NYSE listing standards and applicable SEC rules. Scott Powell will serve as the Chairman of the audit committee. Under the NYSE listing standards and applicable SEC rules, all the directors on the audit committee must be independent. Each member of the audit committee is financially literate and our board of directors has determined that Scott Powell qualifies as an “audit committee financial expert” as defined in applicable SEC rules. Because we expect to list our securities on the NYSE in connection with our initial public offering, we have one year from the date of this offering for our audit committee to have at least three members, all of whom must be independent. The audit committee is responsible for: • meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; • monitoring the independence of the independent registered public accounting firm; • verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; • inquiring and discussing with management our compliance with applicable laws and regulations; • pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the se

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q FORM 10-Q 2022-05-16 https://www.sec.gov/Archives/edgar/data/1877557/000119312522150930/d330058d10q.htm
10-K FORM 10-K 2022-04-01 https://www.sec.gov/Archives/edgar/data/1877557/000119312522092380/d479975d10k.htm
NT 10-K NT 10-K 2022-04-01 https://www.sec.gov/Archives/edgar/data/1877557/000119312522092374/d479975dnt10k.htm
SC 13G SC 13G 2022-02-09 https://www.sec.gov/Archives/edgar/data/1877557/000119312522032737/d307451dsc13g.htm
8-K 8-K 2022-01-13 https://www.sec.gov/Archives/edgar/data/1877557/000119312522007890/d291937d8k.htm
8-K 8-K 2021-12-17 https://www.sec.gov/Archives/edgar/data/1877557/000119312521361117/d253123d8k.htm
SC 13G FORM SC 13G 2021-12-17 https://www.sec.gov/Archives/edgar/data/1877557/000106299321013095/formsc13g.htm
8-K 8-K 2021-12-13 https://www.sec.gov/Archives/edgar/data/1877557/000119312521355407/d269086d8k.htm
424B4 424B4 2021-12-09 https://www.sec.gov/Archives/edgar/data/1877557/000119312521352825/d208572d424b4.htm
EFFECT 2021-12-08 https://www.sec.gov/Archives/edgar/data/1877557/999999999521004609/xslEFFECTX01/primary_doc.xml
3 FORM 3 SUBMISSION 2021-12-08 https://www.sec.gov/Archives/edgar/data/1877557/000089924321047425/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-12-08 https://www.sec.gov/Archives/edgar/data/1877557/000089924321047423/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-12-08 https://www.sec.gov/Archives/edgar/data/1877557/000089924321047421/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-12-08 https://www.sec.gov/Archives/edgar/data/1877557/000089924321047419/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-12-08 https://www.sec.gov/Archives/edgar/data/1877557/000089924321047415/xslF345X02/doc3.xml
S-1/A S-1/A 2021-12-08 https://www.sec.gov/Archives/edgar/data/1877557/000119312521351487/d208572ds1a.htm
CERT NYSE CERTIFICATION 2021-12-07 https://www.sec.gov/Archives/edgar/data/1877557/000087666121001711/WEL120721.pdf
8-A12B 8-A12B 2021-12-07 https://www.sec.gov/Archives/edgar/data/1877557/000119312521349765/d27215d8a12b.htm
CORRESP 2021-12-06 https://www.sec.gov/Archives/edgar/data/1877557/000119312521348831/filename1.htm
CORRESP 2021-12-06 https://www.sec.gov/Archives/edgar/data/1877557/000119312521348830/filename1.htm
S-1/A S-1/A 2021-11-24 https://www.sec.gov/Archives/edgar/data/1877557/000119312521340324/d208572ds1a.htm
S-1 S-1 2021-11-03 https://www.sec.gov/Archives/edgar/data/1877557/000119312521318487/d208572ds1.htm
UPLOAD 2021-09-15 https://www.sec.gov/Archives/edgar/data/1877557/000000000021011211/filename1.pdf
DRS 2021-09-03 https://www.sec.gov/Archives/edgar/data/1877557/000095012321012094/filename1.htm